Deenan Pillay

Summary

Affiliation: University of Birmingham
Country: UK

Publications

  1. ncbi request reprint HIV viral load: the myth of the undetectable?
    Deenan Pillay
    PHLS Antiviral Susceptibility Reference Unit, Public Health Laboratory, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK
    Rev Med Virol 12:391-6. 2002
  2. ncbi request reprint Emergence and control of resistance to antiviral drugs in resistance in herpes viruses, hepatitis B virus, and HIV
    D Pillay
    Birmingham Public Health Laboratory, Birmingham Heartlands Hospital, Bordesley Green East
    Commun Dis Public Health 1:5-13. 1998
  3. ncbi request reprint Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee
    D Pillay
    Division of Immunity and Infection, University of Birmingham Medical School, Edgbaston, UK
    AIDS 14:1111-6. 2000
  4. ncbi request reprint The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population
    D Pillay
    PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham, UK
    Antivir Ther 6:15-24. 2001
  5. ncbi request reprint Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections
    Stephen Taylor
    HPA Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, UK
    Antivir Ther 8:479-83. 2003
  6. ncbi request reprint Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations
    Stephen Taylor
    Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, Birmingham B9 5SS, UK
    AIDS Res Hum Retroviruses 19:353-61. 2003
  7. ncbi request reprint Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000
    Paul Scott
    PHLS Antiviral Susceptibility Reference Unit, Birmingham, UK
    J Antimicrob Chemother 53:469-73. 2004
  8. ncbi request reprint Analysis of HIV-1 variation in blood and semen during treatment and treatment interruption
    Bhudipa Choudhury
    PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham, United Kingdom
    J Med Virol 68:467-72. 2002
  9. ncbi request reprint HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy
    Stephane Hue
    Division of Immunity and Infection, University of Birmingham and Regional Health Protection Agency, Birmingham Heartlands Hospital, London, UK
    AIDS 18:719-28. 2004
  10. ncbi request reprint Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial
    Deenan Pillay
    Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Birmingham Public Health Laboratory, Birmingham, United Kingdom
    J Infect Dis 186:617-25. 2002

Collaborators

Detail Information

Publications66

  1. ncbi request reprint HIV viral load: the myth of the undetectable?
    Deenan Pillay
    PHLS Antiviral Susceptibility Reference Unit, Public Health Laboratory, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK
    Rev Med Virol 12:391-6. 2002
    ..I also consider other possible uses of HIV-1 quantification in clinical practice, such as identifying the inherent potency of antiviral regimens...
  2. ncbi request reprint Emergence and control of resistance to antiviral drugs in resistance in herpes viruses, hepatitis B virus, and HIV
    D Pillay
    Birmingham Public Health Laboratory, Birmingham Heartlands Hospital, Bordesley Green East
    Commun Dis Public Health 1:5-13. 1998
    ..At present, the clearest indication for such testing is in aciclovir-resistant herpes simplex infection. It is important that other resistance assays are subject to studies of clinical utility before their widespread use...
  3. ncbi request reprint Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee
    D Pillay
    Division of Immunity and Infection, University of Birmingham Medical School, Edgbaston, UK
    AIDS 14:1111-6. 2000
    ..A cohort of co-infected patients treated with lamivudine were studied in order to evaluate the differential effects of lamivudine on the two viral populations within the same individual after 44-52 weeks of therapy...
  4. ncbi request reprint The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population
    D Pillay
    PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham, UK
    Antivir Ther 6:15-24. 2001
    ....
  5. ncbi request reprint Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections
    Stephen Taylor
    HPA Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, UK
    Antivir Ther 8:479-83. 2003
    ..We conclude that in the presence of suboptimal ART, sexually transmitted infections may enhance the spread of drug-resistant HIV-1...
  6. ncbi request reprint Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations
    Stephen Taylor
    Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, Birmingham B9 5SS, UK
    AIDS Res Hum Retroviruses 19:353-61. 2003
    ..We provide "proof of principle" that such mutations can therefore become "fixed" within the circulating virus pool...
  7. ncbi request reprint Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000
    Paul Scott
    PHLS Antiviral Susceptibility Reference Unit, Birmingham, UK
    J Antimicrob Chemother 53:469-73. 2004
    ..To establish a surveillance programme for HIV drug resistance within the UK covering the years from 1998 to 2000, following the introduction of triple combination antiretroviral therapy...
  8. ncbi request reprint Analysis of HIV-1 variation in blood and semen during treatment and treatment interruption
    Bhudipa Choudhury
    PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham, United Kingdom
    J Med Virol 68:467-72. 2002
    ..Once successful therapy had been recommenced, it was possible to distinguish distinct populations of virus in the two compartments. These data support the hypothesis that the male genital tract represents a distinct HIV-1 reservoir...
  9. ncbi request reprint HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy
    Stephane Hue
    Division of Immunity and Infection, University of Birmingham and Regional Health Protection Agency, Birmingham Heartlands Hospital, London, UK
    AIDS 18:719-28. 2004
    ..We wished to assess the potential of using HIV-1 pol gene for the identification of transmissions events by phylogenetic means in the era of antiretroviral drug selective pressure...
  10. ncbi request reprint Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial
    Deenan Pillay
    Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Birmingham Public Health Laboratory, Birmingham, United Kingdom
    J Infect Dis 186:617-25. 2002
    ..No differences were observed in the frequency of development of resistance mutations L90M (P=1.00) and D30N (P=.61) in B and non-B viruses. In conclusion, no evidence that subtype determined virologic response to therapy was found...
  11. ncbi request reprint Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients
    Li Xu
    PHLS Antiviral Susceptibility Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham, UK
    AIDS 16:1684-6. 2002
    ..Minimal variation in the HR-1 region of gp41 was observed, especially within the region responsible for T-20 resistance. Any subtype differences in T-20 susceptibility do not appear to be related to HR-1 genetic variation...
  12. ncbi request reprint Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man
    Calman MacLennan
    MRC Centre for Immune Regulation, Division of Immunity and Infection, University of Birmingham, Birmingham, UK
    Lancet 363:1509-13. 2004
    ..Chronic infection with such polioviruses is a recognised complication of hypogammaglobulinaemia...
  13. ncbi request reprint Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors
    David Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:771-7. 2008
    ..These changes might be expected to affect the prevalence and patterns of protease resistance in the population of patients who experience treatment failure...
  14. ncbi request reprint Update of the drug resistance mutations in HIV-1: 2007
    Victoria A Johnson
    Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
    Top HIV Med 15:119-25. 2007
  15. ncbi request reprint HIV resistance and the developing world
    Ravindra Kumar Gupta
    Department of Infectious Diseases, John Radcliffe Hospital, Oxford, UK
    Int J Antimicrob Agents 29:510-7. 2007
    ....
  16. ncbi request reprint The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy
    Deenan Pillay
    Centre for Virology, Division of Infection and Immunity, Royal Free and University College Medical School, Windeyer Institute, 46 Cleveland Street, London W1T 4JF, UK
    AIDS 20:21-8. 2006
    ..Transmission of drug-resistant HIV-1 is well recognized. However, the impact of such transmission on natural history of infection remains unknown...
  17. ncbi request reprint A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial
    Hannah Green
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 11:857-67. 2006
    ..To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure...
  18. pmc HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
    Robert W Shafer
    Division of Infectious Diseases, Stanford University, Stanford, California, USA
    AIDS 21:215-23. 2007
    ..However, such programs will not produce comparable estimates unless a standardized list of drug-resistance mutations is used to define transmitted resistance...
  19. ncbi request reprint Update of the drug resistance mutations in HIV-1: Fall 2005
    Victoria A Johnson
    Veterans Affairs Medical Center, Birmingham, AL, USA
    Top HIV Med 13:125-31. 2005
    ..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility...
  20. ncbi request reprint Update of the drug resistance mutations in HIV-1: Fall 2006
    Victoria A Johnson
    Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
    Top HIV Med 14:125-30. 2006
    ..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility...
  21. ncbi request reprint Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity
    Robert Gifford
    Department of Infection, University College London, UK
    AIDS 20:1521-9. 2006
    ..However, it is not clear how reliable standard genotyping of these sequences is for describing HIV-1 genetic variation and for detecting novel genetic variants and epidemiological trends...
  22. ncbi request reprint Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load
    Daniela Bezemer
    Municipal Health Service Amsterdam, The Netherlands
    Antivir Ther 11:173-8. 2006
    ..043). No difference in HIV-1 RNA load was observed. These results, together with the apparent pressure to mutate at the resistance-associated positions exemplify the decreased fitness of viruses carrying 21 5Y/F, 70R or 184V...
  23. ncbi request reprint Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?
    Katherine J Lee
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 12:949-56. 2007
    ..To investigate transient increases in viral load during sustained suppression in children in the UK and Ireland Collaborative HIV Paediatric Study (CHIPS)...
  24. ncbi request reprint Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 370:1923-8. 2007
    ..We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure...
  25. doi request reprint Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
    Loveleen K Bansi
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London, NW3 2PF, UK
    AIDS 22:349-56. 2008
    ..We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression...
  26. ncbi request reprint Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:675-85. 2008
    ..The aim of this study was to examine factors influencing plasma concentration of efavirenz and nevirapine...
  27. doi request reprint The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom
    Hannah Green
    HIV Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, United Kingdom
    J Acquir Immune Defic Syndr 49:196-204. 2008
    ..The use of different lists of resistance mutations has resulted in estimates of transmitted HIV drug resistance (THDR) that are often not comparable...
  28. pmc Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase
    Richard E Myers
    Virus Reference Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW95EQ, United Kingdom
    J Virol 82:9228-35. 2008
    ..The validation of covariation as a predictive tool will be dependent on monitoring the evolution of HIV-1 integrase under drug selection pressure...
  29. ncbi request reprint UK HIV drug resistance database: background and recent outputs
    David Dunn
    MRC Clinical Trials Unit, London, UK
    J HIV Ther 12:97-8. 2007
  30. ncbi request reprint Antiretroviral resistance in the developing world
    Deenan Pillay
    Department of Virology, University College London, London, UK
    J HIV Ther 12:95-6. 2007
  31. doi request reprint Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
    Martin S Hirsch
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 47:266-85. 2008
    ..As the roll out of antiretroviral therapy continues in developing countries, drug resistance monitoring for both subtype B and non-subtype B strains of HIV will become increasingly important...
  32. doi request reprint Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model
    Andrew N Phillips
    HIV Epidemiology and Biostatistics Group, Department of Primary Care and Population Sciences, and Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, London, UK
    Lancet 371:1443-51. 2008
    ..Our aim was to study the potential consequences of such monitoring strategies, especially in terms of survival and resistance development...
  33. pmc Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006
    Florence Damond
    APHP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris, 75018 France
    J Clin Microbiol 46:2088-91. 2008
    ..Quantification varied between laboratories, and international standardization of quantification assays is strongly needed...
  34. doi request reprint HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004
    Rana Chakraborty
    Paediatric Infectious Diseases Unit, St George s Hospital, London
    Pediatr Infect Dis J 27:457-9. 2008
    ..Three-class resistance was noted in 42 samples (14.1%). Our study also highlighted underutilization of testing and the need for prompt genotyping after drug discontinuation which may have lead to an underestimation of HIV-1 resistance...
  35. doi request reprint Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy
    Christos Mihailidis
    Chelsea and Westminster Hospital NHS Trust, London, UK
    AIDS 22:427-30. 2008
    ..Furthermore, the presence of V118I as the sole nucleoside reverse transcriptase inhibitor mutation should not be over-interpreted when deciding on therapeutic options...
  36. pmc Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study
    Patricia Cane
    BMJ 331:1368. 2005
    ..To examine whether the level of primary resistance to HIV drugs is increasing in the United Kingdom...
  37. ncbi request reprint Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003
    Bernard Masquelier
    Departement de Virologie et Immunologie biologique, CHU Bordeaux, France
    J Acquir Immune Defic Syndr 40:505-11. 2005
    ..To examine factors influencing the rate of transmitted drug resistance (TDR) among seroconverters, with particular emphasis on 3 widely used genotypic drug resistance algorithms...
  38. ncbi request reprint Drug resistance mutations in HIV-1
    Victoria A Johnson
    Veterans Affairs Medical Center, and University of Alabama School of Medicine, Birmingham, AL, USA
    Top HIV Med 11:215-21. 2003
    ..Drugs that have been approved by the US Food and Drug Administration (FDA) or available through expanded access protocols are included...
  39. ncbi request reprint Transmission of HIV-1 drug resistance
    Julian W Tang
    Department of Virology, Windeyer Institute of Medical Sciences, Royal Free and University College Medical Schools, 46 Cleveland Street, London W1T 4JF, UK
    J Clin Virol 30:1-10. 2004
    ..This can lead to the transmission of drug-resistant strains of HIV to susceptible individuals. This can lead to suboptimal first-line therapy, if the resistance profile of the transmitted virus is unknown...
  40. ncbi request reprint The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune response
    Esteban Herrero-Martinez
    Department of Virology, Royal Free and University College Medical School, London, United Kingdom
    J Med Virol 72:187-93. 2004
    ..The relationship disappeared or was obscured after therapy (R = 0.24, P = 0.30 and R = 0.16, P = 0.50, respectively). Thus, we show that HAART affects the HCV specific humoral immune responses without affecting the HCV RNA level...
  41. ncbi request reprint Update of the drug resistance mutations in HIV-1: 2004
    Victoria A Johnson
    Veterans Affairs Medical Center, Birmingham, AL, USA
    Top HIV Med 12:119-24. 2004
  42. ncbi request reprint Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe
    Deenan Pillay
    Department of Virology, Windeyer Institute, Royal Free and University College Medical School, University College London, London, UK
    Antivir Ther 9:695-702. 2004
    ....
  43. ncbi request reprint Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients
    Caroline A Sabin
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 8:301-8. 2003
    ..New formulations of amprenavir, together with boosted regimens, may enhance the activity in the presence of protease inhibitor-resistant virus...
  44. ncbi request reprint Long-term persistence of primary genotypic resistance after HIV-1 seroconversion
    David Pao
    Royal Sussex County Hospital, Brighton, United Kingdom
    J Acquir Immune Defic Syndr 37:1570-3. 2004
    ....
  45. ncbi request reprint Resistance tests: what do clinical trials tell us?
    Nicola Price
    J HIV Ther 7:80-6. 2002
    ....
  46. ncbi request reprint Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections
    David Pao
    Department of GU Medicine, Brighton and Sussex University Hospitals, Brighton, UK
    AIDS 19:85-90. 2005
    ..To study primary HIV-1 infections (PHI) using molecular and epidemiological approaches in order to assess correlates of transmission in this population...
  47. ncbi request reprint Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)
    Diana M Gibb
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 7:293-303. 2002
    ....
  48. ncbi request reprint The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis
    S Tariq Sadiq
    Camden and Islington Community NHS Trust and Department of Sexually Transmitted Diseaeases and Virology, Royal Free and University College Medical School, University College, London, UK
    AIDS 16:219-25. 2002
    ..High seminal plasma HIV-1 RNA loads (SVL) have been reported during gonococcal, non-gonococcal and chlamydial urethritis in patients not taking antiretroviral therapy...
  49. ncbi request reprint Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom
    Deenan Pillay
    Centre for Virology, Royal Free and University College Medical School, University College, London, United Kingdom
    J Infect Dis 192:967-73. 2005
    ..Method 2 also nearly doubles estimates of numbers of individuals infected with multiclass drug-resistant virus. Our results identify an urgent need for new drugs within existing classes and new classes of antiretroviral therapy...
  50. ncbi request reprint The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients
    Alan Winston
    Department of Genitourinary HIV Medicine, Chelsea and Westminster Hospital, London, UK
    AIDS 16:2087-9. 2002
    ..Both genetic routes may compromise abacavir and tenofovir activity...
  51. ncbi request reprint Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance
    Ana T Dumans
    Unidade de Genetica e Biologia Molecular, Universidade Federal do Estado do Rio de Janeiro UNIRIO, Brazil
    J Infect Dis 189:1232-8. 2004
    ..One potential cause of the differences between subtypes is the synonymous codon usage at key resistance positions...
  52. ncbi request reprint Update of the Drug Resistance Mutations in HIV-1: 2005
    Victoria A Johnson
    Veterans Affairs Medial Center, Birmingham, AL, USA
    Top HIV Med 13:51-7. 2005
    ..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that, in isolation, may not reflect prior drug selective pressure or reduced drug susceptibility...
  53. pmc Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
    Rami Kantor
    Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California, USA
    PLoS Med 2:e112. 2005
    ..The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate...
  54. ncbi request reprint Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice
    Andrew N Phillips
    AIDS 19:487-94. 2005
    ..Little is known about the long term risk of development of HIV-1 drug resistance for patients starting antiretroviral therapy (ART) with three or four drug regimens in routine clinical practice...
  55. doi request reprint Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women
    Inmaculada Jarrin
    National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
    Am J Epidemiol 168:532-40. 2008
    ..74, 95% CI: 0.56, 0.98). Sex differences in HIV disease progression have become larger and statistically significant in the era of highly active antiretroviral therapy, supporting a stronger impact of health interventions among women...
  56. ncbi request reprint World Health Organization/HIVResNet Drug Resistance Laboratory Strategy
    Silvia Bertagnolio
    World Health Organization, HIV Department, Geneva, Switzerland
    Antivir Ther 13:49-57. 2008
    ..As of August 2007, assessment for accreditation has been conducted in 30 laboratories, covering the WHO's African, South-East Asia, Western Pacific, and the Caribbean Regions...
  57. ncbi request reprint Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase
    Alan Winston
    Department of GU and HIV Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    AIDS 18:949-51. 2004
  58. ncbi request reprint Determinants of HIV drug resistance mutations in plasma virus after treatment interruption
    Daniella Chilton
    Mortimer Market Centre, Camden Primary Care Trust, London, UK
    AIDS 19:2174-5. 2005
    ..We conclude that resistance testing is of value up to 3 months after treatment interruption, and may convey some benefit up to 12 months...
  59. pmc Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent
    Joke Snoeck
    Rega Institute for Medical Research, Minderbroedersstraat 10, 3000 Leuven, Belgium
    Antimicrob Agents Chemother 50:694-701. 2006
    ..It is not yet known whether therapy response is subtype dependent, but the advice given to clinicians based on a genotypic interpretation algorithm differs according to the subtype...
  60. pmc Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups
    Stephane Hue
    Centre for Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK
    Proc Natl Acad Sci U S A 102:4425-9. 2005
    ..Our results provide insights into the complexity of HIV-1 epidemics that must be considered when developing HIV monitoring and prevention initiatives...
  61. ncbi request reprint Investigation of HIV-1 transmission events by phylogenetic methods: requirement for scientific rigour
    Stephane Hue
    AIDS 19:449-50. 2005
  62. ncbi request reprint Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 21:1717-21. 2007
    ..To assess the absolute rate of AIDS and death in antiretroviral therapy (ART)-naive patients with a high CD4 cell count. Such information would be helpful in the design of a trial investigating early initiation of ART...
  63. pmc HIV phylogenetics
    Deenan Pillay
    BMJ 335:460-1. 2007
  64. ncbi request reprint Clinically validated genotype analysis: guiding principles and statistical concerns
    Francoise Brun-Vezinet
    Hospital Bichat Claude Bernard, Paris, France
    Antivir Ther 9:465-78. 2004
    ....
  65. ncbi request reprint Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters
    Krishnan Bhaskaran
    Medical Research Council Clinical Trials Unit, London, UK
    AIDS 18:1471-3. 2004
    ..The virological and host determinants of this possible phenomenon are worth further exploration...
  66. pmc Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1
    Robert J Gifford
    Department of Infection, University College London, London, United Kingdom
    J Virol 81:13050-6. 2007
    ..The framework implemented here takes advantage of the vast amount of routinely generated HIV-1 sequence data and can provide epidemiological insights not readily obtainable through standard surveillance methods...